Inactief instrument

Koers Ocera Therapeutics Inc

Aandelen

Duur

Periode

Stijl

Ocera Presents Three Posters and an Oral Presentation on OCR-002 at the AASLD Liver Meeting®	20-10-17
Ocera Therapeutics Selected to Present an Oral Presentation and Three Posters on OCR-002 at the AASLD Liver Meeting® 2017	23-08-17
Ocera Therapeutics Reports Second Quarter 2017 Financial Results	01-08-17
Ocera Initiates Phase 2a Study with Oral OCR-002 in Patients with Cirrhosis	01-06-17
Ocera Therapeutics to Host KOL Conference Call on Hepatic Encephalopathy and Other Complications of Liver Disease on Friday, June 2	26-05-17

Sector

	Vaira. 1 jan.	Kapi.
CSL LIMITED	-4,66%	86,13 mld.
SAMSUNG BIOLOGICS CO.,LTD.	+1,32%	39,82 mld.
BIOGEN INC.	-19,27%	30,42 mld.
UCB	+57,86%	25,23 mld.
INCYTE CORPORATION	-17,69%	11,6 mld.
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43,00%	11,51 mld.
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9,14%	11,95 mld.
SWEDISH ORPHAN BIOVITRUM AB	+5,24%	8,71 mld.
INNOVENT BIOLOGICS, INC.	-8,42%	8,12 mld.